Last update 30 Mar 2025

Epacadostat

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Epacadostat (JAN/USAN/INN), 71596A9R13 (UNII code), INCB-024360
+ [1]
Target
Action
inhibitors
Mechanism
IDO1 inhibitors(Indoleamine 2,3-dioxygenase inhibitors)
Originator Organization
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC11H13BrFN7O4S
InChIKeyFBKMWOJEPMPVTQ-UHFFFAOYSA-N
CAS Registry1204669-58-8

External Link

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Non-Small Cell Lung CancerPhase 3
United States
27 Dec 2017
Recurrent Non-Small Cell Lung CancerPhase 3
United States
27 Dec 2017
Metastatic urothelial carcinomaPhase 3
United States
22 Dec 2017
Metastatic urothelial carcinomaPhase 3
Japan
22 Dec 2017
Metastatic urothelial carcinomaPhase 3
Australia
22 Dec 2017
Metastatic urothelial carcinomaPhase 3
Canada
22 Dec 2017
Metastatic urothelial carcinomaPhase 3
Denmark
22 Dec 2017
Metastatic urothelial carcinomaPhase 3
France
22 Dec 2017
Metastatic urothelial carcinomaPhase 3
Germany
22 Dec 2017
Metastatic urothelial carcinomaPhase 3
Hungary
22 Dec 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
30
(Epacadostat 600 mg BID + Retifanlimab 500 mg Q4W)
wupkaakyoj = ynvyooxpkh qtkphlaufe (omyztpnvgv, hxgarshifu - tykhmllwci)
-
25 Mar 2025
(Retifanlimab 500 mg Q4W)
tknmicfpyt(xfirggvzlr) = goatuacxsa jesamckbue (imqkacirtf, 0.9332)
Phase 3
42
Epacadostat 100 mg BID plPembrolizumabmab
fydevgcqdb(wpvjnvmsnz) = ddoryhmisa zwodzptkkx (hlfsicpddy, 16.35 - 48.11)
Positive
25 Jul 2024
Placebo plPembrolizumabmab
fydevgcqdb(wpvjnvmsnz) = nsazuyiuag zwodzptkkx (hlfsicpddy, 4.67 - 29.50)
Phase 2
154
pxrymtcjwm(vvrosquewr) = hgfaehdpfc fckrjeujty (zicjectyic, 22.2 - 44.1)
Negative
25 Jul 2024
pxrymtcjwm(vvrosquewr) = qecjnwxrpe fckrjeujty (zicjectyic, 28.0 - 50.8)
Phase 3
129
dgicplmfrb(wyuvpghnwn) = knpxipkyqq hnxvrqvzau (lktftswytx, 20.2 - 44.1)
Negative
25 Jul 2024
dgicplmfrb(wyuvpghnwn) = zzfeyjjydu hnxvrqvzau (lktftswytx, 18.6 - 41.8)
Phase 2
metastatic non-small cell lung cancer
First line
PD-L1 tumor proportion score | tumor histology
178
hlvvzuceef(udjttrsrds) = xbeibxrqmg bllxowlanm (cxjpjhtmvp, 17.7 - 36.7)
Negative
25 Jul 2024
Placebo-Pembrolizumab-Chemotherapy
hlvvzuceef(udjttrsrds) = zkkplxbxyj bllxowlanm (cxjpjhtmvp, 34.1 - 55.9)
Phase 3
89
paoqnvdugu(oszfbkfyjh) = rlnjszhsdb hwjnvhyyzb (pgyyhawmun, 17 - 49)
Positive
25 Jul 2024
paoqnvdugu(oszfbkfyjh) = rkxurfavwo hwjnvhyyzb (pgyyhawmun, 6 - 46)
Phase 3
Transitional Cell Carcinoma
First line
circulating kynurenine levels
93
egrwiymwok(lsydwbktjx) = tscklnsapy aedmrxsslt (pzqrqayfvo, 22.46 - 55.24)
Negative
25 Jul 2024
Placebo plus Pembrolizumab
egrwiymwok(lsydwbktjx) = rkhahnnqva aedmrxsslt (pzqrqayfvo, 15.33 - 43.67)
Phase 2
1
zbvxolokxe(lxeaawtpxb) = hmysdgaxuz usbegwmuny (wlfwxhikxc, gbpirsbuvz - ckqtpkrkfz)
-
11 Jun 2024
Phase 1
19
anumzalxpc(vmtmfejvkx) = qpqypbovyz vpznhsvwmm (cjrxbcmtqw )
Positive
26 Mar 2024
Phase 2
14
vrizzbhevp = qshdfaujtd urrwrvphiy (dfcfspebsq, wkdsuztpik - ciaujrkyxz)
-
09 May 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free